NO20022157L - Fremgangsmåte for behandling av medikamentavhengighet - Google Patents

Fremgangsmåte for behandling av medikamentavhengighet

Info

Publication number
NO20022157L
NO20022157L NO20022157A NO20022157A NO20022157L NO 20022157 L NO20022157 L NO 20022157L NO 20022157 A NO20022157 A NO 20022157A NO 20022157 A NO20022157 A NO 20022157A NO 20022157 L NO20022157 L NO 20022157L
Authority
NO
Norway
Prior art keywords
drug dependence
treating drug
calcium channel
channel blocker
felodipine
Prior art date
Application number
NO20022157A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022157D0 (no
Inventor
Albert Shulman
Original Assignee
Albert Shulman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9926218.0A external-priority patent/GB9926218D0/en
Priority claimed from GBGB9929595.8A external-priority patent/GB9929595D0/en
Application filed by Albert Shulman filed Critical Albert Shulman
Publication of NO20022157D0 publication Critical patent/NO20022157D0/no
Publication of NO20022157L publication Critical patent/NO20022157L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20022157A 1999-11-06 2002-05-06 Fremgangsmåte for behandling av medikamentavhengighet NO20022157L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9926218.0A GB9926218D0 (en) 1999-11-06 1999-11-06 Composition and method for the treatment of drug abuse
GBGB9929595.8A GB9929595D0 (en) 1999-12-16 1999-12-16 New composition and method for the treatment of drug abuse
PCT/AU2000/001367 WO2001034161A1 (en) 1999-11-06 2000-11-06 A method of treating substance addiction

Publications (2)

Publication Number Publication Date
NO20022157D0 NO20022157D0 (no) 2002-05-06
NO20022157L true NO20022157L (no) 2002-07-04

Family

ID=26316056

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022157A NO20022157L (no) 1999-11-06 2002-05-06 Fremgangsmåte for behandling av medikamentavhengighet

Country Status (9)

Country Link
EP (1) EP1242093A1 (zh)
JP (1) JP2004508274A (zh)
KR (1) KR20020063180A (zh)
CN (1) CN1402638A (zh)
AU (1) AU1256501A (zh)
CA (1) CA2390101A1 (zh)
NO (1) NO20022157L (zh)
NZ (1) NZ518992A (zh)
WO (1) WO2001034161A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
DK2437744T3 (en) * 2009-06-03 2015-07-27 Univ Marquette The modulation of the KCNQ potassium channel activity for the treatment of psychiatric disorders and symptoms thereof
WO2021072213A1 (en) * 2019-10-11 2021-04-15 The Trustees Of Indiana University Pregabalin for treatment of opioid use disorder

Also Published As

Publication number Publication date
CA2390101A1 (en) 2001-05-17
CN1402638A (zh) 2003-03-12
NZ518992A (en) 2004-02-27
WO2001034161A1 (en) 2001-05-17
JP2004508274A (ja) 2004-03-18
EP1242093A1 (en) 2002-09-25
NO20022157D0 (no) 2002-05-06
KR20020063180A (ko) 2002-08-01
AU1256501A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
EE05400B1 (et) Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks
JP2002516258A5 (zh)
EE200300123A (et) Kompositsioon fentanüüli transdermaalseks manustamiseks
EE200200369A (et) Asendatud piperidiinid, neid ühendeid sisaldavad ravimid ja meetodid nende valmistamiseks
NO331093B1 (no) Somatostatinanaloger, fremgangsmåte for fremstilling, farmasøytisk sammensetning og anvendelse derav.
EE05104B1 (et) Asetidiini derivaadid, nende valmistamise meetodid ja farmatseutiline kompositsioon
IS5747A (is) Oxazólidínón afleiður, aðferð fyrir framleiðslu þeirra og lyfjasamsetninga sem innihalda þær
DK1175402T3 (da) Piperidinderivater, der er nyttige som CCR5-antagonister
IS2265B (is) Lyfjablanda sem inniheldur 2-[[(2-pýridínýl)metýl]súlfínýl]bensimídasól með virkni gegn sármyndun og aðferð til að framleiða slíka blöndu
EE200000015A (et) 3- või 4-asendatud 4-(aminometüül)piperidiini bitsüklilised bensamiidid, vaheühend ja farmatseutiline kompositsioon ning nende valmistamismeetodid
EE200000435A (et) Asendatud oksoasaheterotsüklilised ühendid faktori Xa inhibiitoritena, neid sisaldav farmatseutiline kompositsioon ning meetod faktori Xa toime pärssimiseks
HUP0302167A3 (en) Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them
DE69841663D1 (de) Verwendung von methylnaltrexon und verwandten verbindungen
EE04391B1 (et) Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid
IL166795A (en) N - aryl piperidine substituted biphenylcarboxamides, pharmaceutical composiitons comprising them and method for their preparation
ATE283260T1 (de) 1-(1-subst.-4-piperidinyl)methyl)-4-piperidin- derivate, verafhren zu deren herstellung, pharmazeutische mixturen und intermediate zu deren herstellung
DK200000390U1 (da) Farmaceutiske præparater til oral indgivelse, der omfatter paroxetin-methansulfonat.
PL333524A1 (en) Improved prolonged release pharmaceutic preparation for administration of nephadosone, oral dosage form thereof and improved nephadosone administration method
EE200200044A (et) Antisenss-oligonukleotiid või selle derivaat, selle valmistamismeetod ja kasutamine, meetod eg5 ekspressiooni inhibeerimiseks ning farmatseutiline kompositsioon ja selle valmistamismeetod
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
EP1186318A3 (en) Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist
RS11304A (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
NO20022157L (no) Fremgangsmåte for behandling av medikamentavhengighet
AU2000258410A8 (en) New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
HUP0004900A3 (en) Pharmaceutical compositions for treating disease-related or drug-induced dyskinesias containing piperidine derivatives as nmda receptor antagonist as active ingredient

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application